WO1991012237A1 - Derive de sulfonamide de benzene - Google Patents
Derive de sulfonamide de benzene Download PDFInfo
- Publication number
- WO1991012237A1 WO1991012237A1 PCT/JP1991/000149 JP9100149W WO9112237A1 WO 1991012237 A1 WO1991012237 A1 WO 1991012237A1 JP 9100149 W JP9100149 W JP 9100149W WO 9112237 A1 WO9112237 A1 WO 9112237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- amino
- benzenesulfonamide
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/78—Halides of sulfonic acids
- C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/88—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
- C07C2603/66—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing five-membered rings
Definitions
- the present invention relates to a benzenesulfonamide derivative and a pharmacologically acceptable salt thereof, which have excellent action as a medicine.
- Phospholipase A is an enzyme that hydrolyzes the acyl bond of glycerophospholipids, and hydrolyzes the ester bond at position 1 of glycerol lipolipids to decompose the ester bond at position 2. there is a 2 to. Although it is widely distributed in the biological world, it has recently been receiving attention due to its relationship with various diseases.
- phospholipase is activated, membrane phospholipids are disrupted, and the size of the infarct expands, and the relationship with various other disorders is also studied. ing.
- the present inventors have also, has conducted extensive research I cotton in many years for a substance that inhibits the phospho lipase A z of this. Prevention of 'Ma diseases - the result, it has a phospholipase A 2 inhibitory action Ben peptidase Nsuruho N'a mi de derivative or a pharmacologically Ru acceptable salt is excellent below, seeds based on their action ⁇ Treatment, eg prevention of ischemic injury such as myocardial infarction. was found useful. The present invention has been completed based on this finding.
- the compound of the present invention is a sulfonamide derivative represented by the following general formula (I) and a pharmacologically acceptable salt thereof.
- R 2 represents a hydrogen atom or a pyridyl group.
- R 3 represents a hydrogen atom, a lower alkyl group, a cyano group, or a pyryl group.
- R 4 represents a hydrogen atom or a lower alkyl group.
- R 5 and R 6 are the same or different hydrogen atoms, lower alkyl groups, formula-(CH z ) q -A (wherein q is an integer of 1 to 4, and A is hydroxy:
- R 9. R i denotes the same or different hydrogen atom or a lower alkyl group
- R '1 is a hydrogen Hara ⁇ or a lower alkyl group
- g and h each represent an integer of 1 to 4, and B represents a lower alkyl group, a substituted or unsubstituted arylalkyl group, or a substituted or unsubstituted pyridylalkyl group.
- R 5 ; R 6 together form a 6- to 7-membered ring which, in addition to the nitrogen atom to which R 5 : R ′′ is bonded, may also contain a nitrogen atom or an oxygen atom.
- the 6- to 7-membered ring may be substituted with a lower alkyl group, an arylalkyl group, a cycloalkylanolequinole group, or a heteroarylalkyl group, and R 7 is each independently a hydrogen atom, a lower alkyl group. , A lower alkoxy group, or a halogen atom, where r is an integer of 1 or 2, where r is 2 in combination with the two adjacent carbon atoms that make up the benzene ring. M is an integer of 1 or 2 That.) In benzenesulfonyl N'a Mi de derivatives and pharmacologically allowable salts that have the Table.
- the lower alkyl group found in the definitions of R 3 RR-′, R 6 , R 7 , R 11 and B is a group having 1 to 6 carbon atoms.
- Direct or branched alkyl such as For example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl (amyl), isopentyl, neopentyl Group, tert-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1,2-dimethylpropyl group, hexyl group, isohexyl group, 1-methylpentyl group, 2-methylpentyl Group, 3—methylpentyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group
- the lower alkoxy group defined by R 1 and R 7 is a lower alkyl group derived from the lower alkyl group having a prime number of 1 to 6 described above, and a preferred example is, for example, a lower alkyl group.
- halogen atom in the definitions of R 1 and R 7 means chlorine, bromine, iodine, and fluorine.
- Oxygen is attached to the group
- Alkanol groups such as benzoyl, pinoyl, benzoyl, trifluoromethyl, naphthyl, etc., and heteroyl such as froil, nicotinyl, and isonicotinoyl. Examples include an aryl group.
- the heterocoaryl group refers to a group derived from a heterocyclic ring containing nitrogen, oxygen, and sulfur atoms. Specifically, for example, there can be mentioned a bilidyl group, a furyl group and an imidazolyl group, but the most preferred group is an imidazolyl group.
- s is most preferably 4 or 5, that is, the group represented by the formula (CH 2 ) s is represented by the formula
- the unsubstituted cycloalkyl group is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexyl And cycloalkyl groups such as cyclononyl, cyclocodenyl and cyclododecyl groups.
- a substituted cycloalkyl group refers to a cycloalkyl group in which the above cycloalkyl group is substituted with a lower alkyl group such as a methyl group, a halogen atom such as chlorine, and the like, as described below.
- Means that the adjacent carbon atoms that form the ring are condensed with an aromatic ring such as a benzene ring and a heterocyclic ring such as a pyridin ring.
- a bicycloalkyl group and a tricycloalkyl group mean an aliphatic saturated hydrocarbon composed of only two or three rings sharing two or more atoms.
- tricycloalkyl group examples include, for example, an adamantyl group.
- the azabicycloalkyl group means a group in which a nitrogen atom is substituted for any of the carbon atoms constituting the above-mentioned bicycloalkyl group.
- the following groups are mentioned as an example.
- the substituted or unsubstituted arylalkyl group in the definition of B is a lower alkyl group such as a methyl group or an ethyl group, or a lower alkoxy group such as a halogen atom or a methoxy group.
- a lower alkyl group such as a methyl group or an ethyl group, or a lower alkoxy group such as a halogen atom or a methoxy group.
- a substituted pyridylalkyl group is derived from a lower alkyl group such as a methyl or ethyl group, a pyridyl group which may be substituted with a lower alkoxy group such as a halogen atom or a methoxy group.
- a lower alkyl group such as a methyl or ethyl group
- a pyridyl group which may be substituted with a lower alkoxy group such as a halogen atom or a methoxy group.
- R 5 and R 6 are taken together to form a 6- to 7-membered ring which may contain a nitrogen atom or an oxygen atom in addition to the nitrogen atom to which R 5 and R 6 are bonded Is as follows.
- the 6- to 7-membered ring may be substituted with a substituent B, that is, a lower alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, or the like.
- a substituent B that is, a lower alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, or the like.
- the arylalkyl group, cycloalkylalkyl group and heteroarylalkyl group have the same meaning as the groups defined in the above definition.
- R 7 the most preferred case is a hydrogen atom, that is, the case where the phenyl ring is unsubstituted.
- r When r is 2, it forms a ring together with two adjacent carbon atoms that make up a benzene ring Can be.
- the group represented by the formula (R') n is each independently a hydrogen atom, a cyano group, a nitro group, a hydroxyl group, a halogen atom, a halogen atom, A hydroxy group, an acyloxy group, a group represented by the formula: SO 2 —R s (wherein R R represents —kill group), a heterocoaryl group, and a glyco;
- R a , R b , R c , R d are the same or different and are hydrogen atoms, A cyano group, a nitro group, a hydroxyl group, a halogen atom, a lower alkoxy group, an acyl: noxy group, a formula —SO 2 —R 8 (where R 8 represents a lower alkyl group) Group, heteroaryl group, glycyloxy group, formula
- a mono-substituted product refers to a mono-substituted product, a di-substituted product, a tri-substituted product, and a tetra-substituted product substituted with the same or different hydrogen atoms or the above substituents.
- a preferred group is a monoalkylsulfonyl group such as a methylsulfonyl group, an imidazolyl group, a cyano group, or a nitro group mono-substituted at the P-position (4th position) of the fuunyl ring.
- the halogen or hydroxy group is disubstituted (for example, 3—F—4—0H, 3,4 diOH).
- the pharmacologically acceptable salt is a conventional non-toxic salt, for example, an inorganic acid salt such as hydrochloride, hydrobromide, sulfate, sulfate, etc., for example, acetate, Organic acid salts such as maleate, tartrate, methansulfonate, benzenesulfonate, toluenesulfonate, or amides such as, for example, arginine, aspartic acid, glutamate And salts with phosphoric acid.
- an inorganic acid salt such as hydrochloride, hydrobromide, sulfate, sulfate, etc., for example, acetate
- Organic acid salts such as maleate, tartrate, methansulfonate, benzenesulfonate, toluenesulfonate, or amides such as, for example, arginine, aspartic acid, glutamate And salts with phosphoric acid.
- a metal salt such as a sodium salt, a potassium salt, and a potassium salt.
- the compound of the present invention has a double bond, and thus has a cis- or trans-form, that is, a geometric isomer. Needless to say.
- R 1 , R 2 , R 3 , R, R 5 , R 6 m and n have the above-mentioned meanings, and Ac represents an acetyl group.
- X represents a halogen atom.
- the target substance (XIV) when R 1 contains an acetyloxy group or a methoxy group, the target substance (XIV) can also be produced by the following method.
- R e denotes an alkoxy group such as Asechiruokishi group (OAc) or main butoxy group.
- T, u are but t + u ⁇ 4 represents an integer of either 1 to 4.
- R f 0 represents an acyloxy group or a glycyloxy group
- R 6 is a formula
- R 12 represents a protecting group such as a benzyl group or a B0C group.
- E in E represents a substituted or unsubstituted benzyl group Step 14 (hydrolysis)
- R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , B, g, h, m, n has the above meaning
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 12 g, h, m, and n have the above-mentioned meanings.
- R 5 and R 6 are ⁇ to form a 6- to 7-membered ring which may contain a nitrogen atom in addition to the nitrogen atom to which R 5 and R 6 are bonded.
- the ring may have a substituent, the ring can be produced, for example, by the following production method.
- B represents a hydrogen atom or the above-mentioned substituent
- the cinnamic acid derivative (III) is obtained from a ketone or aldehyde (II) obtained by a known or known method by a Wittig reaction, an aldol condensation, or a Knoevenagel reaction. It is a process.
- a Wittig reaction is usually used with an inert solvent such as dimethylformamide, ether, tetrahydrofuran, dioxane, benzene, toluene, dimethyl sulfoxide, or the like.
- Compound (III) can be obtained by an ordinary method also when an aldol condensation or Knebena gel reaction is used.
- This step is a step of hydrolyzing the ester bond of the compound (III) obtained in the first step to obtain a carboxylic acid derivative (IV).
- a carboxylic acid derivative (IV) for example, in a dilute aqueous alkaline solution or a dilute aqueous mineral acid solution, preferably in a 1: 1 mixed solution of a 0.5 to 3 normal aqueous sodium hydroxide solution and ethanol, or in a 2 to 6 aqueous solution.
- the reaction is carried out in a normal aqueous hydrochloric acid solution at room temperature to reflux.
- This step is a step of halogenating the compound (IV) obtained in the second step to obtain an acid halide derivative (V).
- an inert solvent such as dichloromethane, black form, dichloroethane, benzene, and toluene
- oxalic acid chloride thioyuruku light
- React the compound (IV) with phosphorus trichloride, phosphorus tribromide, etc. at room temperature to reflux oxalic acid chloride is more preferable when dimethylformamide is used as a catalyst.
- the compound (V) is not limited to an acid halide derivative, but may be an acid ester, an active ester such as N-hydroxybenzotriazole or N-hydroxysuccinimide.
- a reactive derivative such as a symmetrical acid anhydride, a mixed acid anhydride with alkyl carbonate or p-toluenesulfonic acid or the like can also be used in the seventh step.
- the acetanilide derivative (VI) obtained by a known method or a known method is sulfonylchlorinated to obtain a compound (VII).
- a compound (VII) for example, in an inert solvent such as formaldehyde, dichloroethane, trichloroethane, or benzene, or in the absence of a solvent, an excess amount of chlorosulfonic acid and compound (VI) can be added at room temperature.
- the compound (VII) is obtained by reacting at a temperature of -100'C.
- the chlorsulfon derivative (VII) obtained in the fourth step is reacted with an amide (VIII) obtained by a known or known method to give a sulfonate.
- This is a step of obtaining a nilamide derivative (IX).
- This step is a step of producing an aniline derivative (X) by hydrolyzing the N-acyl group of the sulfonylamide derivative (IX) obtained in the fifth step. It is carried out in a dilute aqueous alkaline solution or a dilute aqueous mineral acid solution. Preferred examples are carried out in a 2-6N aqueous hydrochloric acid solution or in a 0.5-3N aqueous sodium hydroxide solution at 50 to reflux.
- the acid halide or other reactive derivative (V) obtained in the third step is reacted with the aniline derivative (X) obtained in the sixth step to produce the amide derivative (XI) It is a process.
- compound (V) or a reactive derivative thereof and compound (X) are used in almost equimolar amounts or slightly in excess of one, and an organic solvent inert to the reaction, for example, viridine, tetrahydrofuran,
- an organic solvent inert for example, viridine, tetrahydrofuran
- the reaction is performed in a solvent such as dioxane, ethanol, benzene, tosoleene, xylene, dichloromethane, or chloroform.
- diisopropylamino Triethylamine, viridin, picolin, lutidin, N, N-dimethylaminoaniline, 4-dimethylaminovinyl, calcium carbonate, sodium hydroxide, etc.
- the addition of a base is advantageous for smoothly proceeding the reaction.
- the reaction temperature varies depending on the type of the reactive derivative and is not particularly limited. Usually, the reaction is carried out at ⁇ 20 to under heating to reflux, whereby the desired compound (XI) can be obtained.
- hydroxylation in a solvent such as water, methanol, ethanol, propanol, acetonitrile, tetrahydrofuran, or dioxane.
- a base such as sodium, sodium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, or a 0.5 to 6N mineral acid solution During the reaction, 0'c ⁇ heating under reflux and force.
- the alkoxy group of the derivative (XII) containing an alkoxy group such as a methoxy group as R 1 is dealkylated, and the phenol derivative (XIII )),
- boron tribromide, boron trichloride, or triiodide in an inert solvent such as dichloromethane, black form, dichloroethane, or nitrobenzene
- Boron halide compounds such as boron halide
- a dealkylating agent such as an aluminum halide such as aluminum trichloride or aluminum tribromide.
- the reaction is carried out under heating to reflux.
- This step is a step of acylating the phenol derivative ( ⁇ ) obtained in the eighth step or the ninth step to obtain a compound (XIV).
- a compound (XIV) For example: acetonitrile, tetrahydrofuran, dioxane, ether, benzene, toluene, dichloromethan, black mouth form, dimethyl formamide, dimethyl sulfoxide Condensing agents such as dicyclohexane levodimide, 1,1-zolebonolenoresimidazole, 1,2-diethyl ethyl formate, getylazodicarboxylate, and dibilizyl disulphide in inert solvents such as It is preferable to react the funool derivative (XIII) with a carboxylic acid such as an amino acid such as daricin, alanine or norin or a carboxylic acid such as nicotinic acid in the presence of the funosol derivative at a temperature of
- R 12 has a group that can be used as a protecting group for a nitrogen atom, such as a benzyl group, a methoxybenzyl group, a t-butoxycarbonyl group, or a benzyloxycarbonyl group, wherein R 12 is obtained by a known method or a known method.
- the amide derivative (XV) is reacted with the sulfo-uric-mouthed derivative (VII) obtained in the fourth step to produce a sulfonylamide derivative.
- the compound was prepared in the same manner as described in Step 5.
- R 12 is a benzyl group, a methoxybenzyl group, a benzyloxycarbonyl group or the like, it can be removed by a usual method.
- a usual method water methanol, ethanol, propylene glycol, acetate nitrile, dioxan, tetrahydrofuran, ether, ethyl acetate, dimethylformamide Hydrogenation reaction from room temperature to reflux under heating in the presence of catalysts such as,,,,,, R 12 can be removed.
- it is more preferable to coexist acids such as acetic acid and hydrochloric acid.
- R 12 When R 12 is a butoxycarbonyl group or the like, R 12 can be similarly removed by a conventional method.
- a 13 N hydrochloric acid solution using a solvent such as water, methanol, or ethanol can be used. In room temperature at 0 to room temperature.
- Compound (XVI) may be reacted with a fluoro reagent such as ammonium fluoride at 0 ° C. to room temperature.
- the amide derivative (XVII) obtained in the 12th step is N-alkylated to obtain a compound (X).
- the alkylating agent is the compound (XVIII)
- the compound (XVII) may be converted to dimethylformamide, dimethylsulfoxide, or methanol, ethanol, or prothanol.
- Lower alkyl alcohols, such as The compound (XX) can be obtained by reacting the compound (XVIII) with a solvent such as acetone, benzene, or chlorophonolemdichloromethane in the presence of a base at room temperature to heating under reflux.
- the base for example, sodium carbonate, sodium carbonate, sodium hydrogencarbonate, sodium methoxide, sodium ethoxide, sodium hydride, etc. Can be mentioned. Further, if necessary, the reaction may be carried out by adding lithium bromide, lithium iodide, or the like, to give favorable results.
- the alkylating agent is the compound (XIX)
- a polar solvent such as water, methanol, ethanol, dioxane, tetrahydrofuran, and acetonitrile.
- the compound (XIX) and the amide derivative (XVII) are reacted in a mixed solvent of water and water in the presence of a small amount of hydrochloric acid, acetic acid, sodium acetate, etc. at 50'c to heating under reflux. Thereby, the desired compound (XX) can be obtained.
- the formula (XIX) can be represented by the following formula if the unsubstituted or substituted substituent is a lower alkyl group.
- R 13 --ft- CH CH ; ( ⁇ ') Step 14
- This step is a step of hydrolyzing a benzyl group of the compound (XX) obtained in the 13th step to produce an aniline derivative ⁇ ).
- Compound (XXI) can be obtained in the same manner as in Step 6.
- Step 24-Step 13 Next, typical compounds of the present invention will be listed.
- the purpose of the present invention is to facilitate understanding of the present invention, and it goes without saying that the present invention is not limited thereto.
- the compounds are shown in free form.
- N cycloalkyl 4— ⁇ N—methyl—N — [(E) 13 1 (-(1 1 imidazole) phenyl] 1 2—propionyl) amino Benzenesulfo Medium
- N cyclobutinole 4- (N—methyl-N — [(E) —3— (3—funoleo mouth 1-4—hydroxy cyphenyl) 1-2—propionyl] amino ⁇ benzenesulfona Mid
- N cyclohexyl 4— ⁇ N—methyl—N — ((E) 1 3 1 ([3,5—dihydroxy sulfide) 1 2—Propyl) ⁇ ⁇ ⁇ ⁇ ⁇
- N (2—Indanil) 1-4- ⁇ N—methyl-N — [(E) -3— [4-Hydroxy3—Methoxyphenyl) 1-2—Cyan 2 — Prosynthesis ⁇ Amino ⁇ Benzenesulfonamide 91. 4- ⁇ N-C (E)-3-(3, 4-dihydroxycyclophenyl) 1-2-Prodino] amino ⁇ -5,6,7,8-Tetrahi Drawer 1—Naphthalene sulfonamide
- a male NZW heron was anesthetized by intravenous administration of pentobarbitalol, and the heart was removed. After the heart was washed with ice-cold physiological saline, a ventricle was obtained. 5 ml of ice-cooled 0.25M sucrose 20 ⁇ Tris-HCl buffer, pH 8.0 per 1 g of ventricle weight was added, and the mixture was ground with a homogenizer in ice water for 30 seconds. The trituration solution was centrifuged at 1,000 g for 10 minutes, and the supernatant was further centrifuged at 105,000 g ⁇ 60 minutes. Centrifugation was performed at 0-4.
- the resulting supernatant was directly used as a supernatant fraction, and the supernatant was suspended in the above buffer to form a membrane fraction.
- the protein was measured by the Lowry method, and the protein concentration was adjusted to 5 mg Zm1 in each case.
- the prepared membrane fraction contains 100 ⁇ l of lOOmil CaCl 2 solution per 10 ml, and the supernatant fraction has 500 / l of lOOmM ethylene glycol-bis (-aminoethyl ether) per 10 ml.
- ⁇ , ⁇ , ⁇ ', ⁇ ' — EGTA tetraacetic acid The solution was added, and 0.2 ml each was dispensed into a test tube. To each test tube was added the compound solution 21 dissolved in dimethyl sulfoxide (DMS0). For the control, the same amount of DMS0 was added.
- DMS0 dimethyl sulfoxide
- Coronary arteries were ligated using SD male rats (61, weighing 220-300 g) to cause myocardial ischemia. Three hours after ligation, the heart was excised, rings and cut tissue specimens were prepared, and myoglobin staining was performed. The myoglobin II unstained site was defined as the myocardial infarction lesion, and the percentage of the myocardial infarction lesion in the left ventricular area was determined by image analysis to determine the myocardial infarction size.
- the phospholipase 2 inhibitory effect is used as a control drug.
- the present invention compounds are useful phospholipase A 2 inhibitory action as a therapeutic and preventive agent effective various diseases.
- phospholipase A 2 inhibitory action as a therapeutic and preventive agent effective various diseases.
- used as a therapeutic agent for various heart diseases, an antithrombotic agent, etc. I can do it.
- myocardial infarction angina; congestive heart failure with edema, pulmonary congestion, hepatic swelling; TIA (—transient cerebral ischemic attack); cerebral infarction (thrombosis, embolus); Side edema, cerebral vasoconstriction) Cerebrovascular disorders such as cerebral arteriosclerosis; postoperative thrombus and embolism associated with vascular surgery and extracorporeal blood circulation and impaired blood flow; Buerger's disease; obstructive atherosclerosis, SLE or white Treatment and prevention of peripheral blood flow disorder based on obstruction or stenosis of limb arteries such as deafness, and prevention of recurrence of these diseases and improvement of prognosis.
- TIA transient cerebral ischemic attack
- cerebral infarction thrombosis, embolus
- Side edema cerebral vasoconstriction
- Cerebrovascular disorders such as cerebral arteriosclerosis; postoperative thrombus and embolism associated with vascular surgery and
- Araki Don acid metabolites by phospholipase A 2 for example by filtration Nbokisan such as preparative Robokisan A 2, diseases caused by such prostaglandin compounds Roy co preparative Riwen, such inflammatory diseases, Li equine Ji arthritis, asthma ⁇ It is considered to be useful for allergic diseases such as atobi dermatitis.
- the compound of the present invention When the compound of the present invention is used as these medicaments, it is administered orally or parenterally (such as an external preparation for injection suppository).
- the dosage varies depending on the degree of symptoms; age, sex, weight, and sensitivity difference of the patient; administration method; timing of administration, interval, properties of pharmaceutical preparations, preparation, type; type of active ingredient, and is not particularly limited. , Usually about one adult 0.1 to 2,000 mg, preferably about 1 to 1, 000 mg, more preferably about 5 to 500 mg, more preferably about 20 to: 100 mg, usually 1 to 4 times a day. Administer separately.
- the excipient and, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, etc. are added to the active ingredient, and then the tablet is prepared in a conventional manner.
- a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, etc. are added to the active ingredient, and then the tablet is prepared in a conventional manner.
- Excipients include, for example, lactose, corn starch, sucrose, glucose sorbitol, crystalline cellulose, silicon dioxide, and the like.Binders include, for example, polybutyl alcohol, polybutyl ether, ethyl sesolerose, mesylate. Chinoresolesolose, arabic gum, tragacanth, gelatin, shellac, hydroxiflovinolecerose, hydroxypropyl propyl methylcellulose, cassium citrate, dextrin, Lactic acid is permitted to be added to pharmaceuticals as a lubricant, for example, magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc.
- a lubricant for example, magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc.
- the flavoring agents are cocoa powder, peppermint brain, aromatic acid, peppermint oil, dragon brain, cinnamon bark Etc.. Used. Of course, these tablets and granules can be sugar-coated, gelatin-coated and optionally coated as needed.
- a PH preparation a buffer, a suspending agent, a solubilizing agent, a stabilizing agent, a tonicity agent, a preservative, etc. as necessary to the main drug, and then add vein, subcutaneous, Intramuscular injection and intracoronary administration. At that time, if necessary, it can be lyophilized by a conventional method.
- suspending agents include, for example, methylcellulose, polysorbate 80, hydroxyshethylsenorelose, arabian gum, tragacanth powder, carboxymethylcellulose sodium, polyethylene Okishelensorbitan monolaurate can be mentioned.
- dissolution aids for example, polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinic acid amide, polyoxyethylene sorbitan monolaurate, tuna gall, castor oil Fatty acid ethyl esters and the like can be mentioned.
- sodium sulfite, sodium metasulfite, ether and the like can be preserved.
- N-Methylacetanilide (25.0 g, 188. Ommol) was added little by little to chlorosulfonate (62.8ral) under ice cooling. It was added at such a rate that the liquid temperature did not rise above 50, and it took about 10 minutes. After stirring this mixed solution at 80 for 2 hours and 30 minutes, a mixture of ice (200 ml), hexane (30 ml), and isopropyl ether (30 ml) is added little by little at a temperature of 20'c or less under ice-cooling. In addition, excess chlorosulphonic acid was hydrolyzed. The precipitated crystals were collected by filtration and washed with water.
- N- (4-biperidyl) -41- (N-acetyl-N-methylamino) benzenesulfonamide acetate obtained in Production Example 17 (3.71 g, lO.Oraraol), 6 —Methyl-2—Vinyl pyridine (1.43 g, 12.0 MHIOI) and sodium acetate (0.82 g) are dissolved in a mixed solution of methanol (20 ml) and water (20 ml), and the mixture is left for 5 hours. Heated to reflux. To this mixed solution was added sodium hydroxide (3.20 g), and the mixture was heated under reflux for 3 hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69126251T DE69126251T2 (de) | 1990-02-08 | 1991-02-07 | Benzensulfonamidderivat |
EP91903288A EP0468054B1 (en) | 1990-02-08 | 1991-02-07 | Benzenesulfonamide derivative |
JP50382591A JP3176365B2 (ja) | 1990-02-08 | 1991-02-07 | ベンゼンスルホンアミド誘導体 |
NO91913829A NO913829L (no) | 1990-02-08 | 1991-09-30 | Benzensulfonamidderivater. |
FI914726A FI914726A0 (fi) | 1990-02-08 | 1991-10-07 | Bensensulfonamidderivat. |
US08/161,817 US5530118A (en) | 1990-02-08 | 1993-12-06 | Benzenesulfonamide derivatives |
GR970402064T GR3024421T3 (en) | 1990-02-08 | 1997-08-13 | Benzenesulfonamide derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2/27071 | 1990-02-08 | ||
JP2707190 | 1990-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991012237A1 true WO1991012237A1 (fr) | 1991-08-22 |
Family
ID=12210837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000149 WO1991012237A1 (fr) | 1990-02-08 | 1991-02-07 | Derive de sulfonamide de benzene |
Country Status (12)
Country | Link |
---|---|
US (3) | US5281626A (ja) |
EP (1) | EP0468054B1 (ja) |
JP (1) | JP3176365B2 (ja) |
AT (1) | ATE153655T1 (ja) |
CA (1) | CA2050591A1 (ja) |
DE (1) | DE69126251T2 (ja) |
DK (1) | DK0468054T3 (ja) |
ES (1) | ES2100943T3 (ja) |
FI (1) | FI914726A0 (ja) |
GR (1) | GR3024421T3 (ja) |
NO (1) | NO913829L (ja) |
WO (1) | WO1991012237A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7329755B2 (en) | 2002-12-23 | 2008-02-12 | Millennium Pharmaceuticals, Inc. | CCR8 inhibitors |
US7378525B2 (en) | 2002-12-23 | 2008-05-27 | Millennium Pharmaceuticals, Inc. | CCR8 inhibitors |
US7491827B2 (en) | 2002-12-23 | 2009-02-17 | Millennium Pharmaceuticals, Inc. | Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
US7618960B2 (en) | 2005-11-24 | 2009-11-17 | Eisai R&D Management Co., Ltd. | Morpholine type cinnamide compound |
US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
US7713993B2 (en) | 2006-03-09 | 2010-05-11 | Eisai R&D Management Co., Ltd. | Multi-cycle cinnamide derivatives |
US7737141B2 (en) | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
US7923563B2 (en) | 2004-10-26 | 2011-04-12 | Eisai R&D Management Co., Ltd. | Amorphous object of cinnamide compound |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
US8008293B2 (en) | 2007-02-28 | 2011-08-30 | Eisai R&D Management Co., Ltd. | Bicyclic oxomorpholine derivative |
US8048878B2 (en) | 2005-11-24 | 2011-11-01 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
US9453000B2 (en) | 2007-08-31 | 2016-09-27 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
JP2020528405A (ja) * | 2017-07-21 | 2020-09-24 | ヴァーシテック・リミテッドVersitech Limited | 化合物及び微生物感染治療のためのその使用 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0468054B1 (en) * | 1990-02-08 | 1997-05-28 | Eisai Co., Ltd. | Benzenesulfonamide derivative |
WO1996040982A1 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Therapeutic inhibition of phospholipase a2 in neurodegenerative disease |
US5866318A (en) * | 1995-06-07 | 1999-02-02 | Athena Neurosciences, Inc. | Inhibition of phospholipase A2 to reduce neuronal cell death |
US5707821A (en) * | 1995-06-07 | 1998-01-13 | Athena Neurosciences, Inc. | Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease |
US5994398A (en) * | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
US6518424B1 (en) | 1998-11-12 | 2003-02-11 | Elan Pharmaceuticals, Inc. | Substituted pyrimidine compositions and methods of use |
US6521632B2 (en) * | 2000-02-11 | 2003-02-18 | Oy Juvantia Pharma Ltd | Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor |
WO2003101177A2 (en) * | 2002-06-04 | 2003-12-11 | Sequenom, Inc. | Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions |
EP1581095A4 (en) * | 2002-06-27 | 2006-10-18 | Harkness Pharmaceuticals Inc | THERAPEUTIC METHODS FOR REDUCING FAT DEPOSIT AND TREATING THE DISEASES THEREOF |
US20050239077A1 (en) * | 2002-06-27 | 2005-10-27 | Adam Gail I R | Diagnosing predisposition to fat deposition and associated conditions |
DE60222185T2 (de) * | 2002-12-02 | 2008-06-12 | Council Of Scientific And Industrial Research | Verfahren zur Prävention und/oder Behandlung von Asthma mit Parabromophenacyl Bromide |
ZA200609845B (en) * | 2004-05-26 | 2010-02-24 | Eisai R&D Man Co Ltd | Cinnamide compound |
WO2007058305A1 (ja) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | シンナミド誘導体の製造方法 |
WO2007058304A1 (ja) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | シンナミド化合物の塩またはそれらの溶媒和物 |
US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
PT2035369E (pt) | 2006-07-05 | 2014-09-30 | Fibrotech Therapeutics Pty Ltd | Compostos terapêuticos |
JPWO2008140111A1 (ja) * | 2007-05-16 | 2010-08-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド誘導体のワンポット製造方法 |
CA2709937C (en) * | 2007-12-21 | 2016-03-22 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
CA2712095A1 (en) * | 2008-01-28 | 2009-08-06 | Eisai R&D Management Co., Ltd. | Crystalline cinnamide compounds or salts thereof |
WO2010144959A1 (en) * | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
IN2012DN03312A (ja) | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
CN103288752B (zh) * | 2013-06-21 | 2016-06-22 | 广西大学 | 肉桂酸酰胺衍生物、制备方法及其在制备止血化瘀药物中的应用 |
US11014873B2 (en) | 2017-02-03 | 2021-05-25 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
PE20240545A1 (es) * | 2020-12-18 | 2024-03-19 | Amphista Therapeutics Ltd | Moleculas bifuncionales novedosas para la degradacion de proteinas dirigidas |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60255749A (ja) * | 1984-05-31 | 1985-12-17 | Univ Nagoya | キノン誘導体 |
GB8531019D0 (en) * | 1985-12-17 | 1986-01-29 | Beecham Group Plc | Compounds |
KR870011086A (ko) * | 1986-05-29 | 1987-12-19 | 벤자민 에프. 램버트 | 포스포리파제 a₂억제제 및 그의 합성방법 |
JPS63258854A (ja) * | 1987-04-16 | 1988-10-26 | Mitsubishi Kasei Corp | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 |
JP2670626B2 (ja) * | 1988-12-28 | 1997-10-29 | 株式会社豊田中央研究所 | 車両の姿勢制御装置 |
EP0468054B1 (en) * | 1990-02-08 | 1997-05-28 | Eisai Co., Ltd. | Benzenesulfonamide derivative |
-
1991
- 1991-02-07 EP EP91903288A patent/EP0468054B1/en not_active Expired - Lifetime
- 1991-02-07 AT AT91903288T patent/ATE153655T1/de not_active IP Right Cessation
- 1991-02-07 WO PCT/JP1991/000149 patent/WO1991012237A1/ja active IP Right Grant
- 1991-02-07 DE DE69126251T patent/DE69126251T2/de not_active Expired - Fee Related
- 1991-02-07 DK DK91903288.8T patent/DK0468054T3/da active
- 1991-02-07 CA CA002050591A patent/CA2050591A1/en not_active Abandoned
- 1991-02-07 US US07/768,515 patent/US5281626A/en not_active Expired - Fee Related
- 1991-02-07 JP JP50382591A patent/JP3176365B2/ja not_active Expired - Lifetime
- 1991-02-07 ES ES91903288T patent/ES2100943T3/es not_active Expired - Lifetime
- 1991-09-30 NO NO91913829A patent/NO913829L/no unknown
- 1991-10-07 FI FI914726A patent/FI914726A0/fi not_active Application Discontinuation
-
1993
- 1993-12-06 US US08/161,817 patent/US5530118A/en not_active Expired - Fee Related
-
1995
- 1995-12-29 US US08/581,257 patent/US5663414A/en not_active Expired - Fee Related
-
1997
- 1997-08-13 GR GR970402064T patent/GR3024421T3/el unknown
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 104(19), 168072q (R. J. CREMLYN et al.), May 12, 1986 (12. 05. 86). * |
J. Med. Chem., Vol. 30(9), 1595-8 (C. A. MAYFIELD et al.), September 30, 1987 (30. 09. 87). * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7329755B2 (en) | 2002-12-23 | 2008-02-12 | Millennium Pharmaceuticals, Inc. | CCR8 inhibitors |
US7378525B2 (en) | 2002-12-23 | 2008-05-27 | Millennium Pharmaceuticals, Inc. | CCR8 inhibitors |
US7491827B2 (en) | 2002-12-23 | 2009-02-17 | Millennium Pharmaceuticals, Inc. | Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
US8063222B2 (en) | 2002-12-23 | 2011-11-22 | Millennium Pharmaceuticals, Inc. | Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
US7880009B2 (en) | 2004-05-26 | 2011-02-01 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
US7687640B2 (en) | 2004-05-26 | 2010-03-30 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
US7923563B2 (en) | 2004-10-26 | 2011-04-12 | Eisai R&D Management Co., Ltd. | Amorphous object of cinnamide compound |
US8048878B2 (en) | 2005-11-24 | 2011-11-01 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
US7618960B2 (en) | 2005-11-24 | 2009-11-17 | Eisai R&D Management Co., Ltd. | Morpholine type cinnamide compound |
US7897632B2 (en) | 2006-03-09 | 2011-03-01 | Eisai R&D Management Co., Ltd. | Multi-cyclic cinnamide derivatives |
US7973033B2 (en) | 2006-03-09 | 2011-07-05 | Eisai R&D Management Co., Ltd. | Multi-cyclic cinnamide derivatives |
US7713993B2 (en) | 2006-03-09 | 2010-05-11 | Eisai R&D Management Co., Ltd. | Multi-cycle cinnamide derivatives |
US7737141B2 (en) | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
US8008293B2 (en) | 2007-02-28 | 2011-08-30 | Eisai R&D Management Co., Ltd. | Bicyclic oxomorpholine derivative |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
US9453000B2 (en) | 2007-08-31 | 2016-09-27 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
JP2020528405A (ja) * | 2017-07-21 | 2020-09-24 | ヴァーシテック・リミテッドVersitech Limited | 化合物及び微生物感染治療のためのその使用 |
Also Published As
Publication number | Publication date |
---|---|
NO913829D0 (no) | 1991-09-30 |
DK0468054T3 (da) | 1997-06-16 |
DE69126251T2 (de) | 1997-09-25 |
NO913829L (no) | 1991-12-06 |
US5530118A (en) | 1996-06-25 |
EP0468054A4 (en) | 1993-11-10 |
GR3024421T3 (en) | 1997-11-28 |
US5281626A (en) | 1994-01-25 |
JP3176365B2 (ja) | 2001-06-18 |
CA2050591A1 (en) | 1991-08-09 |
EP0468054B1 (en) | 1997-05-28 |
ES2100943T3 (es) | 1997-07-01 |
ATE153655T1 (de) | 1997-06-15 |
US5663414A (en) | 1997-09-02 |
EP0468054A1 (en) | 1992-01-29 |
DE69126251D1 (de) | 1997-07-03 |
FI914726A0 (fi) | 1991-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991012237A1 (fr) | Derive de sulfonamide de benzene | |
RU2128644C1 (ru) | Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе | |
EP1303483B1 (en) | Novel thiourea derivatives and the pharmaceutical compositions containing the same | |
KR101496190B1 (ko) | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체 | |
US7459585B2 (en) | Benzene derivatives and pharmaceutical use thereof | |
US5914332A (en) | Retroviral protease inhibiting compounds | |
US8071618B2 (en) | Caspase inhibitors and uses thereof | |
US5395839A (en) | Imidazopyridine derivatives and their use | |
JP5832447B2 (ja) | ビスアシル化ヒドロキシルアミン誘導体 | |
JP2016094394A (ja) | N−アシルオキシスルホンアミドおよびn−ヒドロキシ−n−アシルスルホンアミド誘導体 | |
IE49318B1 (en) | Imidazole derivatives | |
JPH11139969A (ja) | 医薬組成物 | |
HU215833B (hu) | Szubsztituált (kinolin-2-il-metoxi)-fenil-acil-szulfonamidok és -ciánamidok, és ezeket tartalmazó gyógyszerkészítmények, és eljárás ezek előállítására | |
WO1996034856A1 (en) | 2-ureido-benzamide derivatives | |
AU616014B2 (en) | Butenoic or propenoic acid derivative | |
EP0579618B1 (en) | Pyridine- and imidazole-derived agents for cardiovascular diseases | |
JP2006509790A (ja) | 心不全の治療のための混合されたPDE阻害およびβアドレナリン拮抗薬活性または部分的作用薬活性を有する化合物 | |
CA2653039C (en) | Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics | |
WO2003059265A2 (en) | Compositions and methods for treating heart failure | |
FI114862B (fi) | Menetelmä terapeuttisesti käyttökelpoisten bentseenialkaanihappojen valmistamiseksi ja välituotteet | |
KR100281867B1 (ko) | 3-(비스-치환페닐메틸렌)옥신돌유도체 | |
SK105395A3 (en) | Arylbenzoylguanidines | |
JPH07267954A (ja) | 新規の3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1ノナン−化合物、その製法及び抗不整脈剤 | |
JP3342475B2 (ja) | ナトリウム−水素交換1型阻害物質を調製する方法 | |
SK283634B6 (sk) | Butadiénový, aminobutadiénový a pyrolidínový derivát a spôsoby ich prípravy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2050591 Country of ref document: CA Ref document number: 1991903288 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 914726 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1991903288 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991903288 Country of ref document: EP |